Table 3 Comparison of the ROC curve, IDI and category-free NRI of the Cr vs. Cr, UPCR vs. Cr, UPCR, cMet/Cr in predicting ESRD.
From: Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
AUC (95% CI) | DeLong test | IDI | category-free NRI | |||
|---|---|---|---|---|---|---|
P-value | P-value | (95% CI) | P-value | (95% CI) | ||
ESRD | ||||||
Cr | 0.858 (0.808, 0.907) | Reference | Reference | Reference | ||
cMet/Cr | 0.694 (0.623, 0.765) | <0.0001 | <0.0001 | <0.0001 | ||
Cr+UPCR | 0.889 (0.846, 0.931) | 0.0389 | 0.0001 | 6.52% (3.18%, 9.87%) | <0.0001 | 88.31% (65.02%, 111.61%) |
Cr+UPCR+cMet/Cr | 0.890 (0.848, 0.933) | 0.0295 | 0.0001 | 6.76% (3.38%, 10.15%) | <0.0001 | 82.64% (59.07%, 106.22%) |
Death | ||||||
Cr | 0.644 (0.569, 0.720) | Reference | Reference | Reference | ||
cMet/Cr | 0.620 (0.536, 0.704) | 0.5943 | 0.0748 | 0.1726 | ||
Cr+UPCR | 0.633 (0.556, 0.710) | 0.5717 | 0.4641 | 0.32% (−0.53%, 1.17%) | 0.3923 | 11.95% (−15.42%, 39.31%) |
Cr+UPCR+cMet/Cr | 0.641 (0.558, 0.724) | 0.9138 | 0.0372 | 2.76% (0.16%, 5.35%) | 0.8453 | −2.82% (−31.11%, 25.47%) |
Composite | ||||||
Cr | 0.865 (0.818, 0.911) | Reference | Reference | Reference | ||
cMet/Cr | 0.694 (0.626, 0.761) | <0.0001 | <0.0001 | <0.0001 | ||
Cr+UPCR | 0.878 (0.835, 0.922) | 0.149 | 0.0196 | 2.86% (0.46%, 5.27%) | <0.0001 | 81.06% (57.53%, 104.59%) |
Cr+UPCR+cMet/Cr | 0.886 (0.844, 0.928) | 0.0555 | 0.0005 | 4.78% (2.10%, 7.46%) | <0.0001 | 74.21% (50.30%, 98.12%) |
